Skip to main content
The Globe and Mail
Support Quality Journalism.
The Globe and Mail
First Access to Latest
Investment News
Collection of curated
e-books and guides
Inform your decisions via
Globe Investor Tools
Just$1.99
per week
for first 24 weeks

Enjoy unlimited digital access
Enjoy Unlimited Digital Access
Get full access to globeandmail.com
Just $1.99 per week for the first 24 weeks
Just $1.99 per week for the first 24 weeks
var select={root:".js-sub-pencil",control:".js-sub-pencil-control",open:"o-sub-pencil--open",closed:"o-sub-pencil--closed"},dom={},allowExpand=!0;function pencilInit(o){var e=arguments.length>1&&void 0!==arguments[1]&&arguments[1];select.root=o,dom.root=document.querySelector(select.root),dom.root&&(dom.control=document.querySelector(select.control),dom.control.addEventListener("click",onToggleClicked),setPanelState(e),window.addEventListener("scroll",onWindowScroll),dom.root.removeAttribute("hidden"))}function isPanelOpen(){return dom.root.classList.contains(select.open)}function setPanelState(o){dom.root.classList[o?"add":"remove"](select.open),dom.root.classList[o?"remove":"add"](select.closed),dom.control.setAttribute("aria-expanded",o)}function onToggleClicked(){var l=!isPanelOpen();setPanelState(l)}function onWindowScroll(){window.requestAnimationFrame(function() {var l=isPanelOpen(),n=0===(document.body.scrollTop||document.documentElement.scrollTop);n||l||!allowExpand?n&&l&&(allowExpand=!0,setPanelState(!1)):(allowExpand=!1,setPanelState(!0))});}pencilInit(".js-sub-pencil",!1); // via darwin-bg var slideIndex = 0; carousel(); function carousel() { var i; var x = document.getElementsByClassName("subs_valueprop"); for (i = 0; i < x.length; i++) { x[i].style.display = "none"; } slideIndex++; if (slideIndex> x.length) { slideIndex = 1; } x[slideIndex - 1].style.display = "block"; setTimeout(carousel, 2500); } //

New data from the Canadian Venture Capital and Private Equity Association shows domestic companies in the life sciences sector, anchored by biotechnology firms that develop new therapies, raised $1.03-billion in venture capital (VC) in the first nine months of the year.

Kkolosov

Canada’s booming biotechnology sector continues to be the bright spot in the country’s pandemic-challenged early-stage investment landscape.

New data from the Canadian Venture Capital and Private Equity Association shows domestic companies in the life sciences sector, anchored by biotechnology firms that develop new therapies, raised $1.03-billion in venture capital (VC) in the first nine months of the year.

That is up 16 per cent over the same period in 2020, leaving the sector likely to surpass 2019′s full-year record of $1.05-billion.

Story continues below advertisement

B.C. biotech firms AbCellera Biologics and Chinook Therapeutics raised $144-million and $140-million, respectively earlier this year, the two highest rounds of funding for Canadian companies so far in 2020.

Meanwhile, companies in the information and communications technology sector raised $1.875-billion in VC, down 39 per cent year over year, while agriculture and clean technology startups saw the total amount of VC dollars slump by more than 70 per cent.

Overall, there were 413 VC deals through September 30 that raised $3.5-billion, compared to 397 deals and $4.7-billion in the same period a year earlier. Refinitiv also recently reported a third-quarter slowdown in Canadian VC activity compared to last year.

That follows a stronger second quarter than the previous year, which CVCA president Kim Furlong said was attributable to venture capitalists injecting cash into portfolio companies, partially matched by funds to help them get through the pandemic from federal crown corporates Business Development Bank of Canada and Export Development Canada.

The third quarter slowdown “to me is a signal that this is not necessarily a bull market in Canada,” Ms. Furlong said. “There’s still a lot of work to be done for Canada to continue to grow and to be seen as a place where we’re creating and growing strong companies.”

The biotechnology sector has had a breakout year in Canada, including the two largest initial public offerings ever by Canadian firms in the sector, Repare Therapeutics and Fusion Pharmaceuticals, in June. They could be surpassed by AbCellera, a Vancouver antibody therapy developer which revealed plans late last week to go public on Nasdaq. Equity financing by Canadian biotechs this year have surpassed $3.4-billion, more than three times 2019 levels. There are now four Nasdaq-listed Canadian biotechnology companies valued at US$1-billion or more.

Cedric Bisson, a partner with Montreal fund-of-funds investment firm Teralys Capital, said Canada’s strong biotech performance mirrors a global boom. “It reflects the quality of companies but also hopefully greater investor appetite for the sector, which is highlighted by [the search for treatments for] COVID but a number of other factors.”

Story continues below advertisement

The sector is benefiting from several breakthroughs in recent years, including the mapping of the human genome, advances in cell therapy, development of antibodies and the use of computer modeling and artificial intelligence in drug discovery to more rapidly identify drug candidates and devise more targeted approaches to treat diseases. Several drug developers, including AbCellera in partnership with Eli Lilly, have been able to rapidly identify, test and seek regulatory approval for promising COVID-19 treatments in just months, a process that can take years.

The companies have been fueled by strong support from international investors in both private and public markets. But Mr. Bisson noted few Canadian institutional investors other than a handful of big funds in Quebec are active in the sector, adding he hoped that growing investor interest in Canadian software companies would “translate into large backers also joining on the bandwagon and investing in Canadian [biotech] companies as well.”

In fact, the three biggest life sciences venture deals this year were almost entirely funded by foreign venture capital firms. Canada’s four main life sciences-focused venture funds – Amplitude Venture Capital, CTI Life Sciences Fund, Genesys Capital and Lumira Ventures – are in the process of raising their latest funds.

Your time is valuable. Have the Top Business Headlines newsletter conveniently delivered to your inbox in the morning or evening. Sign up today.

Your Globe

Build your personal news feed

  1. Follow topics and authors relevant to your reading interests.
  2. Check your Following feed daily, and never miss an article. Access your Following feed from your account menu at the top right corner of every page.

Follow the author of this article:

Follow topics related to this article:

View more suggestions in Following Read more about following topics and authors
Report an error Editorial code of conduct
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

If you do not see your comment posted immediately, it is being reviewed by the moderation team and may appear shortly, generally within an hour.

We aim to have all comments reviewed in a timely manner.

Comments that violate our community guidelines will not be posted.

Read our community guidelines here

Discussion loading ...

To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies